Overview

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)

Phase:

N/A

Details

Lead Sponsor:

The Cleveland Clinic

Collaborator:

Mallinckrodt

Treatments:

Adrenocorticotropic Hormone